Ultrasound-guided SoracteLite™ transperineal laser ablation (TPLA) of the prostate for the treatment of symptomatic benign prostatic hyperplasia (BPH): a prospective single-center experience
Antonino Laganà, Giovanni Di Lascio, Aldo Di Blasi, Leslie Claire Licari, Antonio Tufano, Rocco Simone Flammia, Andrea De Carolis
Abstract
Abstract Purpose To evaluate the efficacy and safety of ultrasound-guided transperineal laser ablation (TPLA) in patients with symptomatic BPH. Materials and methods From January 2020 to January 2022, 63 prospectively enrolled patients underwent TPLA with a 1064-nm continuous-wave diode laser (EchoLaser, Elesta SpA). Primary endpoints were the change in IPSS, QoL, Q max , PVR and prostate volume at 3 and 12 months. Results At 3 months, IPSS improved from 20.8 ± 7.4 to 11.0 ± 6.6 ( p < 0.001), QoL from 4.7 ± 1.4 to 1.5 ± 1.2 ( p < 0.001) and Q max from 8.6 ± 3.5 mL/s to 13.2 ± 5.7 mL/s ( p = 0.083). PVR decreased from 124.8 ± 115.4 mL to 43.6 ± 53.6 mL ( p < 0.001), and prostate volume decreased from 63.6 ± 29.7 mL to 45.6 ± 21.8 mL ( p = 0.003). At 12 months, IPSS improved from 20.8 ± 7.4 to 8.4 ± 5.9 ( p < 0.001), QoL from 4.7 ± 1.4 to 1.2 ± 0.8 ( p < 0.001), and Q max from 8.6 ± 3.5 mL/s to 16.2 ± 4.3 mL/s ( p = 0.014). PVR decreased from 124.8 ± 115.4 mL to 40.6 ± 53.6 mL ( p = 0.003), and prostate volume decreased from 63.6 ± 29.7 mL to 42.8 ± 14.2 mL ( p = 0.071). Transient complications consisted of two patients with prostatic abscess (Clavien-Dindo grade IIIa) and one patient with orchitis (Clavien-Dindo grade II). Conclusions TPLA for symptomatic BPH provides clinical benefits at 3 and 12 months, and the treatment is well tolerated.